Secondary Hyperparathyroidism clinical trials at UCLA
1 research study open to eligible people
Showing trials for
Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
open to eligible people ages 0-18
This is a Phase 3 Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Los Angeles, California and other locations
Our lead scientists for Secondary Hyperparathyroidism research studies include Isidro Salusky.
Last updated: